Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases

Katugampola, Ruwani P., Anstey, Alexander Vincent, Finlay, Andrew Yule, Whatley, Sharon D., Woolf, Jacqueline, Mason, Nicola G., Deybach, J. C., Puy, H., Ged, C., de Verneuil, H., Hanneken, S., Minder, E., Schneider-Yin, X. and Badminton, Michael Norman 2012. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. British Journal Of Dermatology 167 (4) , pp. 888-900. 10.1111/j.1365-2133.2012.11154.x

Full text not available from this repository.

Abstract

Background Congenital erythropoietic porphyria (CEP) is an autosomal recessive photomutilating porphyria with onset usually in childhood, where haematological complications determine prognosis. Due to its extreme rarity and clinical heterogeneity, management decisions in CEP are often difficult. Objectives To develop a management algorithm for patients with CEP based on data from carefully characterized historical cases. Methods A single investigator collated data related to treatments and their outcomes in 29 patients with CEP from the U.K., France, Germany and Switzerland. Results Six children were treated with bone marrow transplantation (BMT); five have remained symptomatically cured up to 11Æ5 years post-transplantation. Treatments such as oral charcoal, splenectomy and chronic hypertransfusion were either of no benefit or were associated with complications and negative impact on health-related quality of life. Lack of consistent genotype–phenotype correlation meant that this could not be used to predict disease prognosis. The main poor prognostic factors were early age of disease onset and severity of haematological manifestations. Conclusions A management algorithm is proposed where every patient, irrespective of disease severity at presentation, should receive a comprehensive, multidisciplinary clinical assessment and should then be reviewed at intervals based on their predicted prognosis, and the rate of onset of complications. A BMT should be considered in those with progressive, symptomatic haemolytic anaemia and ⁄or thrombocytopenia. Uroporphyrinogen III synthase genotypes associated with poor prognosis would additionally justify consideration for a BMT. Rigorous photoprotection of the skin and eyes from visible light is essential in all patients.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RL Dermatology
Publisher: Blackwell Publishing
ISSN: 0007-0963
Last Modified: 13 Nov 2017 23:54
URI: http://orca.cf.ac.uk/id/eprint/42791

Citation Data

Cited 13 times in Google Scholar. View in Google Scholar

Cited 32 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item